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There is an expanding field of research investigating the benefits of alternatives to current pharmacological therapies in psychiatry. 
N-acetylcysteine (NAC) is emerging as a useful agent in the treatment of psychiatric disorders. Like many therapies, the clinical origins
of NAC are far removed from its current use in psychiatry. Whereas the mechanisms of NAC are only beginning to be understood, it is
likely that NAC is exerting benefits beyond being a precursor to the antioxidant, glutathione, modulating glutamatergic, neurotropic and
inflammatory pathways. This review outlines the current literature regarding the use of NAC in disorders including addiction, compulsive
and grooming disorders, schizophrenia and bipolar disorder. N-acetylcysteine has shown promising results in populations with these dis-
orders, including those in whom treatment efficacy has previously been limited. The therapeutic potential of this acetylated amino acid is
beginning to emerge in the field of psychiatric research.
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Historical use of N-acetylcysteine
N-acetylcysteine (NAC) has been used as an antioxidant pre-
cursor to glutathione (γ-glutamylcysteinylglycine; GSH) in
the treatment of paracetamol overdose for more than
30 years.1 As more is understood about the actions of NAC,
the clinical applications have also broadened. N-acetylcysteine
is now widely used as a mucolytic and in the treatment 
of HIV, and it has reported efficacy in chronic obstructive
pulmonary disease and contrast-induced nephropathy.2 Spe-
cific to brain disorders, NAC has been trialled with some effi-
cacy in patients with Alzheimer disease.3 The present review
will explore the role of NAC in the treatment of psychiatric
conditions and the possible mechanisms of benefit for these
disorders.
Role in oxidative homeostasis
The use of NAC in restoring GSH levels is well established
(Fig. 1). Glutathione is the primary endogenous antioxidant.
Glutathione neutralizes reactive oxygen and nitrogen species
from the cell through both direct and indirect scavenging. As
the most abundant and ubiquitous antioxidant, it is respon -
sible for maintaining the oxidative balance in the cell. This oc-
curs through both direct removal of reactive species through
the formation and breakdown of adducts and is also cata -
lyzed by glutathione peroxidase (GPx) in a nicotinamide
 adenine dinucleotide phosphate (NADPH)–dependent reac-
tion. The resulting oxidized glutathione is then reduced by
glutathione reductase to begin the cycle again.4 Glial cells
contain much higher levels of GSH than neuronal cells and
support neuronal GSH production. Astrocytes release GSH
into the extracellular space and γ-glutamyltranspeptidase
breaks down GSH to a cysteine–glycine dipeptide and gluta-
mate. The dipeptide is hydrolyzed to glycine and cysteine,
and all 3 amino acids are then available for neuronal GSH
synthesis. Neuronal GSH production is believed to be pri-
marily mediated by astrocytic GSH release, and astrocytic
GSH production is rate-limited by cysteine and the enzyme
glutamate–cysteine ligase.4,5
In addition to providing cysteine for GSH production,
NAC has been shown to scavenge oxidants directly, par -
ticularly the reduction of the hydroxyl radical, ·OH and
hypochlorous acid.6
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Oral administration of GSH alone does not adequately re-
store GSH levels. It is rapidly hydrolyzed by the liver and in-
testines,7 and penetration through the blood– brain barrier is
poor. Similarly, oral administration of L- cysteine has also
been shown to have little effect on brain GSH levels owing to
first-pass metabolism.8–10 Oral NAC administration results in
increased plasma cysteine levels, ultimately leading to in-
creases in plasma GSH.11,12 N- acetylcysteine has been shown
to successfully penetrate the blood– brain barrier and raise
brain GSH levels in animal models,13–15 which may be relevant
to psychiatry, where alterations in brain GSH and other re-
dox pathways have been shown.
Interaction with inflammatory mediators
Alterations in pro- and anti-inflammatory cytokines, includ-
ing interleukin (IL)-6, IL-1β and tumour necrosis factor
(TNF)–α, have been reported in populations with depression,
and to a lesser extent, bipolar disorder and schizophrenia.16,17
These inflammatory cytokines are potential contributors 
Fig. 1: Mechanisms of action of N-acetylcysteine (NAC). Top to bottom: increased activity of cystine–glutamate antiporter results in increased
activation of metabotropic glutamate receptors on inhibitory neurons and facilitates vesicular dopamine release; NAC is associated with re-
duced levels of inflammatory cytokines and acts as a substrate for glutathione synthesis. These actions are believed to converge upon mech -
an isms promoting cell survival and growth factor synthesis, leading to increased neurite sprouting. BDNF = brain-derived neurotrophic factor;
IL = interleukin; NADP = nicotinamide adenine dinucleotide phosphate; NADPH = reduced form of NADP; TNF = tumour necrosis factor.
to the underlying pathophysiology of these disorders. 
N- acetylcysteine has been shown to have anti-inflammatory
properties (Fig. 1) that are linked to oxidative pathways,
which may provide another potential mechanism of action in
the benefits of NAC in psychiatry.
N- acetyl cysteine has been shown to reduce IL-6 levels in
hemodialysis patients,18 although no change in these levels
were reported following NAC treatment in a rat model of
traumatic brain injury.19 Conversely, increased TNF-α and 
IL-1β levels were reduced following NAC treatment in rat
models of both traumatic brain injury and focal cerebral
 ischemia.19,20 N- acetyl cysteine has also been shown to im-
prove outcomes in lipopolysaccharide models of inflamma-
tion. Pretreatment with NAC prevented oxidative stress and
loss of long-term potentiation following exposure to prenatal
inflammation.21 Furthermore, lipopolysaccharide treatment
results in inhibited oligodendroglial cell development and
myelination that is attenuated by NAC administration in rat
mixed glial  cultures.22
The reductions in inflammatory cytokines by NAC treat-
ment may be a potential mechanism by which NAC modu-
lates the symptoms of psychiatric disorders. This may be di-
rectly associated with the inflammatory pathway, or working
through oxidative processes associated with inflammation.
Further research is required to elucidate these mechanisms.
Effects on neurotransmission
Glutamate
In addition to the effects on oxidative balance, alterations in
cysteine levels have also been shown to modulate neuro-
transmitter pathways, including glutamate and dopamine
(DA; Fig. 1).23,24 Cysteine assists in the regulation of neuronal
intra- and extracellular exchange of glutamate through the
 cystine– glutamate antiporter. Whereas this antiporter is ubi -
quitous throughout all cell types, in the brain it is preferen-
tially located on glial cells.25 The dimer, cystine, is taken up
by astrocytes and exchanged for glutamate, which is released
into the extracellular space. This free glutamate appears to
stimulate inhibitory metabotropic glutamate receptors on
glutamatergic nerve terminals and thereby reduce the synap-
tic release of glutamate.26 Given that relation, the amount of
cysteine in the system as well as the feedback via GSH pro-
duction by neurons may directly regulate the amount of glu-
tamate present in the extracellular space. Furthermore, GSH
itself has been shown to potentiate brain N-methyl-D-
 aspartate receptor response to glutamate in rats.27,28 Changes
in the levels of neuronal GSH may not only alter available
glutamate levels, but also have direct consequences on gluta-
matergic function.
Dopamine
In addition to modulating glutamate levels through the
 cystine– glutamate antiporter, NAC has also been shown to
alter DA release. Following amphetamine treatment to rat
striatal slices, NAC has been shown to facilitate vesicular DA
release at low doses in striatal neurons and inhibit release at
millimolar concentrations.29 In monkeys, NAC has been
shown to protect against reductions in DA transporter levels
following repeated methamphetamine administration,30 sug-
gesting one mechanism whereby increased DA release was
facilitated in the previous study. Glutathione has also been
shown to increase glutamate agonist–evoked DA release in
mouse striatal neurons.23
Use in psychiatry
There is a growing body of literature exploring the use of
NAC in the treatment of psychiatric illness. There is provi-
sional evidence of the potential benefit of NAC in a wide
range of disorders. Many of these disorders have limited
treatment options or suboptimal outcomes with current treat-
ments. The present review outlines the clinical use of NAC in
psychiatry (summary in Table 1).
Addiction
There is an abundance of literature implicating glutamatergic
abnormalities in addiction.47,48 More recently, data are emerg-
ing suggesting a role of oxidative stress in the pathophysiol-
ogy of addiction to drugs of abuse.32,49–51 Research has explored
the modulation of glutamatergic pathways by NAC in pre-
clinical models.52,53 N- acetyl cysteine has been shown to reverse
the decline in cystine–glutamate exchange through the
 cystine– glutamate antiporter and thereby assist in the restora-
tion of glutamatergic pathways in addiction.32,52 These proper-
ties have made it a potential prospect for the treatment of ad-
diction. Much of the following literature is based on small
clinical trials, nonrandomized cohorts or case reports, but is
sufficiently promising to suggest the need for larger well de-
signed studies.
Marijuana dependence
A recent study by Gray and colleagues31 investigated the use
of NAC (2400 mg/d) in an open-label study of 24 dependent
marijuana users who reported an interest in reducing their
use. Following treatment, users reported reductions in
days/week of use and “number of hits.” Conversely, urine
cannabinoid meas ures did not significantly change over the
treatment period, although the authors state that urine
cannabinoid levels in 13 users remained higher than the de-
tection range of the test, thus providing ambiguous results
regarding decreases in use. In addition to overall use, reduc-
tions in reported compulsivity, emotionality and purposeful-
ness regarding marijuana use (measured with the Marijuana
Craving Questionnaire) were reported, reflecting an im-
provement in 3 of the 4 domains of the scale.31
Nicotine addiction
N- acetyl cysteine has also been investigated as a treatment for
nicotine addiction. In addition to the modulation of gluta-
mate to reduce cravings and reward behaviours, NAC may
have a role as an antioxidant in a disorder where oxidative
stress is marked. There has been 1 placebo-controlled study
Dean et al.
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Table 1: Summary of clinical findings of N-acetylcysteine (NAC) treatment in psychiatric illness
Study Disorder
No. study
participants
Total daily
dose, mg Study design Outcome measures Findings
Gray et al.31 Marijuana
addiction
24 2400 4-wk open-label trial Marijuana Craving Questionnaire Improvement in 3 of the 4 domains of the
scale
Knackstedt
et al.32
Reduction in
nicotine use
29 2400 4-wk double-blind
placebo-controlled trial
Questionnaire for Smoking Urges-
Brief, Minnesota Nicotine
Withdrawal Scale
Trend for improvement after covarying
for alcohol use but overall a negative trial
Van Schooten
et al.33
Chemo-
prevention trial
in healthy
smokers
(unable to quit)
41 1200 6-mo double-blind
placebo-controlled trial
Cotinine (plasma and BAL fluid),
urine mutagenicity, 4-ABP-Hb
adducts, lipophilic-DNA adducts
(PBL and BAL cells), 8-OH-dG
adducts (BAL cells), PAH-DNA
adducts (MFC and BMC),
micronuclei (MFC and SPC), TEAC
(plasma and BAL fluid)
Decreases in lipophilic DNA adducts,
8-OH-dG levels and number of
micronuclei
LaRowe
et al.34
Cocaine
addiction
13 2400 Crossover design,
treatment for 2 d in
each arm (NAC and
placebo)
CSSA, self-reported cocaine use,
reported cravings, routine blood
tests
Significant decrease in craving,
withdrawal and self-reported use in NAC
but not placebo group (no between-
group differences)
LaRowe
et al.35
Cocaine
addiction
15 2400 Crossover design,
treatment for 2 d in
each arm (NAC and
placebo)
Cue-reactivity (general and
motivational measures)
Decreased desire and interest in cocaine
and reduced time spent looking at
cocaine-related slides
Mardikian
et al.36
Cocaine
addiction
23 1200,
2400 and
3600
4-wk, open-label trial Days and amount of money spent
on cocaine, CSSA and urine drug
screen
Nonsignificant trends in reductions of
amount spent and number of days of use
on cocaine and improvements based on
CSSA
Grant et al.37 Pathological
gambling
29 O/L
16 random
1800† 8-wk O/L study
followed by a 6-wk
double-blind, placebo-
controlled trial (in
responders only)
Y-BOCS adapted for Pathological
Gambling (PGYBOCS), G-SAS, CGI
Improvement and Severity scales,
Sheehan Disability Scale, HAM-D,
HAM-A, Quality of Life Inventory
Decreased PG-YBOCS scores during
O/L phase. Sixteen of original 27 were
classified as responders, 13 of whom
continued to double-blind phase. There
was an increased number of continued
response in the NAC group and trends
toward significance in the PG-YBOCS
and G-SAS scales.
Lafleur et al.38 OCD 1 3000† 13 wk Y-BOCS and HAM-D Improvements between baseline and
end point on Y-BOCS and HAM-D
Odlaug et al.39 TTM 2 1800 10 and 13 wk Self-reported behaviour Complete abstinence from hair pulling
Grant et al.40 TTM 50 1200–2400 12-wk double-blind,
placebo-controlled trial
MGH-HPS, CGI, PITS, Sheehan
Disability Scale, Quality of Life
Scale, HAM-A and HAM-D
Significant improvements in MGH-HPS,
PITS, CGI severity scale scores in the
NAC group compared with placebo
Odlaug et al.39 Nail biting 1* 1800† 13 wk Self-reported behaviour Complete abstinence from nail biting
after 9 weeks of treatment. A 2-week
hiatus caused reinstatement of
symptoms, but subsequent NAC
treatment again ameliorated this.
Berk et al.41 Nail biting 3 2000 6 mo Self-reported behaviour Complete abstinence of symptoms that
continued after 1-month washout period
Odlaug et al.39 Skin picking 1 1800† 13 wk Self-reported behaviour Decreased urge and act of skin picking
Berk et al.42 Schizophrenia 140 2000 6-mo double-blind
placebo-controlled trial
PANSS, CGI, GAF, SOFAS, BAS,
Simpson–Angus Scale and the
Abnormal Involuntary Movements
Scale
Improvements seen in negative
symptoms based on PANSS;
improvements also seen on CGI and
BAS. Improvements were lost at the
1-month follow-up visit.
Lavoie et al.12 Schizophrenia 11 2000 8-wk double-blind
crossover design
Mismatched negativity and plasma
glutathione concentration
Significant improvements in mismatch
negativity in NAC group. Plasma
glutathione levels were increased
following NAC treatment.
Bulut et al.43 Schizophrenia 1 600 30 d PANSS, CGI and Calgary
depression scale
Reduction in PANSS and CGI scores
Berk et al.44 Bipolar disorder 76 2000 6-mo double-blind
placebo-controlled trial
MADRS, Bipolar Depression Rating
Scale, Young Mania Rating Scale,
CGI-bipolar version, GAF, SOFAS,
SLICE/LIFE, LIFE-RIFT, and the
Quality of Life Enjoyment and
Satisfaction Questionnaire
Positive results showed improvements
on most rating scales (including primary
outcome measure MADRS) in NAC
group compared with placebo group
BAL = bronchoalveolar lavage; BAS = Barnes Akathisia Scale; BMC = buccal mucosa cell; CGI = Clinical Global Impression; CSSA = Cocaine Selective Severity Assessment;
GAF = Global Assessment of Functioning; G-SAS = Gambling Symptom Assessment Scale; HAM-A = Hamilton Rating Scale for Anxiety; HAM-D = Hamilton Rating Scale for Depression;
LIFE-RIFT = Longitudinal Interval Follow-up Evaluation Range of Impaired Functioning Tool; MADRS = Montgomery–Åsberg Depression Rating Scale; MFC = mouth floor cell;
MGH-HPS = Massachusetts General Hospital Hair Pulling Scale; OCD = obsessive–compulsive disorder; O/L = open label; PAH = polycyclic aromatic hydrocarbon; PANSS = Positive
and Negative Symptoms Scale; PBL = peripheral blood lymphocyte; PITS = Psychiatric Institute Trichotillomania Scale; random. = randomized; SLICE/LIFE = Streamlined Longitudinal
Interview Clinical Evaluation from the Longitudinal Interval Follow-up Evaluation; SOFAS = Social and Occupational Functioning Scale; SPC = soft palate cell; TEAC = trolox equivalent
antioxidant capacity; TTM = trichotillomania; Y-BOCS = Yale–Brown Obsessive Compulsive Scale.
*This participant also had TTM.
†Titrated dose.
(n = 29) investigating 2400 mg/day of NAC as a treatment for
tobacco cessation.32 This study recorded participant ratings of
use and cravings as well as biochemical measures to confirm
reported use. There was no significant difference in the num-
ber of cigarettes smoked or carbon monoxide levels between
NAC and placebo groups. Treatment adherence and side ef-
fects were not reported. The authors noted that alcohol was a
significant covariate, and after the removal of 2 outliers based
on alcohol consumption and resulting nicotine use, there was
only a post hoc trend toward decreased number of cigarettes
smoked in the NAC group, and this did not correspond with
decreased carbon monoxide levels. Owing to the exclusion of
participants from the analysis and the variability of the sam-
ple in terms of extraneous factors such as alcohol use, the
sample size of this study was too small to make definitive
conclusions.
There is another small-scale study that specifically in-
cluded smokers who were not planning on quitting that in-
vestigated biomarkers in smokers after NAC treatment.33 The
outcome of the study was to assess the effects of NAC on the
detrimental biophysical aspects of smoking. Participants
were randomly assigned to placebo or NAC (1200 mg/d)
groups and treated for 6 months. The study found that in the
NAC group, there were decreases in lipophilic DNA adducts
between baseline and end point. Also, 8-OH-dG levels were
decreased both between baseline and end point, and com-
pared to the placebo group. These data indicate a decrease in
DNA damage over the course of the study. Additionally,
there was a decreased number of micro nuclei present in oral
mucosa in the NAC group after treatment when compared
with baseline.
Cocaine addiction
In a small crossover study (n = 13), designed to determine
tolerability and safety, participants (currently abstaining
from cocaine use) were given 2400 mg of NAC or placebo
over 2 days.34 Four days later, participants were crossed over
to the alternative arm. Whereas there was no between-group
change in reduction of cravings compared with placebo, the
within-group analysis showed that the NAC group had a sig-
nificant reduction in cravings, withdrawals and self-reported
use compared with baseline, which was not seen in the
placebo group. Whereas this study did not aim to investigate
efficacy, a signal was found that provided some evidence to
justify further research.
In a follow-up study, a similar sample was treated with
2400 mg of NAC.35 Results of this study showed that, based
on cue-reactivity slides, NAC reduced the desire for and in-
terest in cocaine, and also reduced the amount of time spent
looking at the cocaine-related slides.
After these studies, this research group went on to conduct
a larger open-label trial of NAC using 3 doses over 4 weeks.36
Initially, 8 participants received 1200 mg/day of NAC. After
the establishment of tolerability at this dose, a further 9 par-
ticipants received 1800 mg/day of NAC, and finally 6 partici-
pants received 3600 mg/day of NAC. Although not statis -
tically significant, this study found reductions in the amount
spent on cocaine, the number of days of use and improve-
ments based on the Cocaine Selective Severity Assessment.
The researchers noted that this study was underpowered and
required a placebo-controlled design to make concrete asser-
tions regarding the efficacy of NAC in the treatment of co-
caine addiction. Considering these results, larger well de-
signed trials are required.
Pathological gambling
In an open-label study involving 29 participants with a con-
firmed pathologic addiction to gambling, Grant and col-
leagues37 administered 1800 mg (titrated dose) of NAC over
8 weeks. A randomized trial of 13 responders was then con-
ducted over the following 6 weeks (constant dose of
1800 mg/kg of NAC compared with placebo). During the
open-label study, 16 participants experienced significant re-
ductions in gambling behaviour. Of those, 13 agreed to take
part in the randomized study. Following a further 6 weeks of
NAC treatment, 83% of the NAC group was still considered
responders, with only 28% in the placebo group.
Obsessive–compulsive disorder
Similarities exist among brain regions implicated in addiction
and obsessive–compulsive disorder (OCD), including the
 nucleus accumbens and anterior cingulate cortex.54,55 There
have been reports of oxidative stress in populations with
 OCD, including increased lipid peroxidation;56–59 decreased
vitamin E,58 catalase, GPx and selenium;59 increased superoxide
dismutase;59 and changes in overall oxidative status.60 Some of
these alterations have been linked to symptom severity.57,59
Standard first-line therapies for OCD generally include a
combination of serotonin reuptake inhibitors (SRIs) and psy-
chotherapy. Whereas there is some efficacy with this treat-
ment regimen, up to 20% of individuals with OCD are
 treatment-resistant and derive little benefit.61 There is some
evidence to suggest glutamatergic abnormalities in individ -
uals with OCD; however, further characterization is required
to determine if this is a primary, causal effect or a by-product
of hypermetabolism and altered neurotransmission in other
pathways.62
At present, there is only 1 case report regarding the use of
NAC in patients with OCD.38 This report showed notable
benefits in an individual who was treatment-refractory. The
participant experienced partial benefit from treatment with
fluvoxamine, and continued fluvoxamine during a 13-week
trial of 3 g of NAC (including dose titration to 3 g). During
the course of the trial, the participant improved on both
Yale–Brown Obsessive Compulsive Scale and Hamilton Rat-
ing Scale for Depression scores. Continued treatment with
fluvoxamine and NAC led to dramatic improvements in con-
trol of compulsive washing and obsessional triggers.
Trichotillomania and grooming disorders
A spectral relation between OCD and trichotillomania (TTM)
is described, and there is reported efficacy of SRIs in TTM, as
with OCD.63 However, the response to treatment with SRIs in
individuals with TTM is inconsistent.64 Comparisons between
Dean et al.
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TTM and addictive disorders have also been made, given that
impulsivity and dysfunctional reward pathways may be oper-
ative in both types of disorder, and there has been some bene-
fit in treating TTM with opioid antagonists.65 Trichotillomania
may have a heterogeneous nature, with one subgroup more
similar to OCD and another subgroup more similar to addic-
tion.66 Two case studies suggested benefits of NAC treatment
in individuals with TTM.39 The first involved a 28-year-old
man and the second a 40-year-old woman. These authors re-
ported that 1800 mg of NAC (titrated over a period of several
weeks) ameliorated hair pulling.
There has been 1 double-blind, placebo-controlled trial of
NAC for the treatment of TTM.40 In this study, 50 individuals
(45 women and 5 men) were given 1200 mg of NAC or
placebo for 6 weeks, followed by a further 6 weeks of
2400 mg of NAC or placebo. Half of the sample was concur-
rently taking medication, including SRIs, serotonin-
 noradrenaline reuptake inhibitors and stimulants. Four par-
ticipants were undergoing psychotherapy. N- acetyl cysteine
was administered in combination with these treatments.
Over the course of the study, NAC treatment was found to
decrease symptoms of TTM compared with placebo. Most
(88%) of the participants completed the 12-week study. Ef-
fects of treatment were seen at week 9 and continued
throughout the remainder of the study. Overall, NAC
seemed to be efficacious in the treatment of TTM.
In addition to TTM, promising preliminary results suggest
the need for controlled studies in other grooming disorders,
including nail biting and skin picking.39,41 A case report was
published regarding an individual with both TTM and nail
biting behaviours, in whom nail biting ceased following
9 weeks of NAC treatment.39 The participant relapsed after a
hiatus in treatment, but recommencement of NAC resulted in
a remission of symptoms.39 A serendipitous finding of the
benefit of NAC treatment in the reduction of nail biting in a
study primarily investigating NAC (2000 mg/d) in the treat-
ment of mood disorders has been reported.41 Three partici-
pants taking NAC reported significant reductions in nail
 biting during the 6-month course of treatment. All 3 partici-
pants were still abstinent from nail biting 1 month after the
discontinuation of NAC.
Finally, there is a case report regarding skin picking and
NAC treatment.39 In a woman who was not receiving
pharma cological interventions, 600 mg/day of NAC was ad-
ministered. Over the subsequent 4 weeks, the dose was in-
creased to 1800 mg/day, after which both urge and actual
 behaviours regarding skin picking had completely remitted.
Schizophrenia
Dopaminergic abnormalities have historically been in the fore -
ground as research targets for schizophrenia, although all other
major neurotransmitter systems, including γ-aminobutyric
acid, serotonin, acetylcholine, glutamate and noradrena -
line have also been implicated.65 Increased dopaminergic
metab olism in the striatum has been reported. This hyper -
 dopaminergic state has been shown to inversely correlate
with hypodopaminergia in the prefrontal cortex. These
changes are believed to mediate alterations in executive func-
tion and many of the positive symptoms of the disorder.
In populations with schizophrenia, dysfunction in gluta-
mate metabolism and decreased glutamate levels in the pre-
frontal cortex have been reported.68 The addition of cysteine
has been shown to modulate glutamate levels through
 glutamate– cystine exchange, and GSH has been shown to
modulate the binding of glutamate to N-methyl-D-aspartate
receptors.69 N- acetyl cysteine may be beneficial in the treat-
ment of schizophrenia by targeting both oxidative stress and
glutamatergic dysfunction, suggesting that the phenotype is
a result of interactions of multiple neurotransmitter path-
ways70 that interact with oxidative and inflammatory sys-
tems, which are additionally implicated in the  disorder.
There is an expanding body of evidence suggesting oxida-
tive stress occurs in individuals with schizophrenia, and
there are links between oxidative stress symptom severity
and diagnostic subtype.45,71–74 Whether the effects are syn -
chron ous with altered neurotransmission or the result of
these abnormalities requires further research. Evidence for a
role of oxidative stress in populations with schizophrenia
 includes polymorphisms in key GSH pathway genes and al-
tered levels of antioxidants (with correlations between levels
and severity of symptoms).75 Oxidative stress may lead to
changes in lipid membranes, mitochondrial dysfunction and
alterations to DNA and proteins. In individuals with schizo-
phrenia, it is believed that whereas there are few changes to
neur onal cell bodies, connections and dendritic sprouting
may be affected. This is one potential mechanism by which
oxidative stress is involved in this disorder. Similarly,
changes in mitochondrial function have been reported, and
the link to energy generation may provide a clue to the
under lying pathology of schizophrenia. Moreover, links be-
tween oxidative stress and neurotransmission in psychiatric
illnesses are beginning to be identified.
A large-scale study investigating NAC as an adjunctive
therapy for schizophrenia has been conducted,42 which em-
ployed a 1000 mg, bi-daily regimen (compared with placebo)
in addition to existing medication over 6 months. In all,
140 participants took part in this double-blind, placebo-
 controlled, randomized trial. Of these, 60% completed the 
6-month treatment trial. Improvements were seen in the
nega tive symptoms, measured on the Positive and Negative
Symptoms Scale. Furthermore, improvements in global func-
tion and improved abnormal movements, particularly
akathisia, were also reported. These effect sizes were moder-
ate, and improvements were lost 1 month after the discon -
tinu ation of treatment. This sample was considered treat-
ment-refractory, with the average duration of illness being
12 years and more than 60% of participants medicated with
clozapine. Given this, the outcomes of the addition of NAC
are noteworthy. Gastrointestinal side effects were most com-
monly reported; however, the NAC and placebo groups did
not differ  statistically.
These findings were further supported by qualitative
analysis of participants’ data. In this report, using a novel
methodology, qualitative analysis of patient reports and 
clinician observations was performed in a blinded manner,
and the NAC and placebo groups were compared. Emerging
themes showed that participants treated with NAC demon-
strated improvements in insight, self-care, social interaction,
motivation, volition, psychomotor stability and stabilization
of mood.76 In a subset of the primary study, NAC appeared to
modulate auditory sensory processing, measured using mis-
match negativity, a marker of glutamatergic function and an
endophenotype of psychosis. Compared with healthy con-
trols, individuals with schizophrenia were shown to have re-
duced mismatch negativity at baseline. Following 8 weeks of
NAC treatment (2000 mg/d), mismatch negativity was
shown to improve significantly.12 A recent case report has
also shown significant improvements in symptoms following
600 mg/day of NAC in a young woman with treatment-
 resistant schizophrenia. However, details of total length of
treatment are not provided.43
Bipolar disorder
Alterations in oxidative metabolism have also been described
in populations with bipolar disorder.61,77 Similar to schizo-
phrenia, changes in antioxidant levels, increased markers of
lipid peroxidation and protein carbonylation have all been
reported. These changes appear to be related to state, particu-
larly in mania, where increased oxidative stress seems to be
apparent. This is congruent with reports of hyperdopaminer-
gic states during manic episodes.46 Furthermore, links be-
tween oxidative status and duration of illness have also been
found.78
A double-blind, randomized, placebo-controlled trial of
NAC in 75 participants with bipolar disorder was con-
ducted.44 This 6-month trial involved the addition of
2000 mg/d of NAC or placebo to treatment as usual. Over
the 6-month per iod there was no difference between groups
in drop-out rates, with 64% of the total sample completing
the trial.  Rating scores on the Montgomery–Åsberg Depres-
sion Rating Scale (MADRS) and the Bipolar Depression Rat-
ing Scale showed large decreases in depressive symptoms
(about 9 points on the MADRS between NAC and placebo
groups at the end point). Akin to the schizophrenia trial, im-
provements were seen on global improvement, severity and
function scales; however, these effects were proportionally
larger, with large effect sizes on most measures. Again, after
discontinuation of NAC treatment, there was a convergence
with scores between the NAC and placebo groups, showing a
loss of benefit following washout.
Discussion
N-acetylcysteine appears to be promising in the treatment of
several psychiatric disorders. Many of the psychiatric dis -
orders discussed have shown only preliminary data regard-
ing the efficacy of NAC in their treatment, and further re-
search is required. However, NAC appears to be a promising
therapeutic target and provides a window of treatment op-
portunity in a field where current treatments are limited or
have remained suboptimal.
The apparent lack of specificity of NAC in initial studies is
intriguing and suggests that it may be targeting pathways
that are common across disorders; oxidative stress appears to
be a fairly nonspecific finding in a range of psychopatholo-
gies, and dysregulation of glutamate, inflammatory path-
ways and DA are similarly widely reported. Given that the
current diagnostic systems are phenomenologically based,
and that in no other branch of medicine are phenomenology
and pathophysiology linearly linked, this may reflect an in-
trinsic limitation of our classification system. This is high-
lighted by the fact that there is extensive overlap of other
treatments and biomarkers across disorders. As the body of
evidence is currently provisional for many disorders, as the
evidence base expands, it is possible that the efficacy will ap-
pear to be greater in some areas than others. Additionally,
the precise dose of NAC remains to be definitively estab-
lished. Dose-finding studies may reveal greater efficacy at
higher doses or equal efficacy at lower doses. Whereas the
tolerability profile of NAC appears benign, it needs to be
stressed that there is no extensive evidence base with longer-
term use. Some adverse events, such as pulmonary hyperten-
sion are reported in very high-dose animal studies, but have
not been seen in human studies.79 Whereas NAC appears to
be antiepileptic at low doses,80 seizures are reported with
overdose.81 Vigilance is necessary.
Given that many of these disorders have many interacting
potential pathophysiological pathways, further research is re-
quired to determine how NAC is exerting benefits. Bio-
marker and neuroimaging platforms have the capacity to 
illuminate these issues. In disorders such as addiction, gluta-
mate has been the primary candidate for the mechanism of
action, whereas in schizophrenia and mood disorders, the
GSH hypothesis has been the one postulated as explaining
the mechanism of action of NAC. However, given the inter-
action between glutamate, the most abundant neurotransmit-
ter, and other neurotransmitter pathways, including DA and
serotonin, individuals with disorders such as depression and
schizophrenia may benefit by indirect modulation of these
pathways through changes in glutamatergic function. A com-
mon link in treatment efficacy may be oxidative stress, which
has been shown to be altered in most of these disorders.
However, in cocaine addiction, most of the research focusing
on mechanisms of action has implicated the modulation of
the cystine–glutamate antiporter by NAC as the most likely
cause of benefit.26,82,83 Whereas there are similarities across
these disorders with alterations to oxidative biology and
neuro transmission, and changes in glutamate- dependent
long-term potentiation and neuronal plasticity,84 perhaps the
heterogeneity of the underlying pathologies, especially in
brain regions implicated, may lead to the revelation of differ-
ent actions of NAC depending on the disorder.
Similarly, the modulation of inflammatory pathways may
also play a role in the benefits seen following NAC treatment.
The role of inflammation in depression has received the
greatest attention; however, inflammatory pathways are im-
plicated in the etiology of other disorders, such as schizo-
phrenia. As with the atypical antipsychotics, which have new
data showing a diversity of mechanisms of action, including
on inflammation,85 brain-derived neurotrophic factor86 and
Dean et al.
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oxidative stress,87 efficacy may turn out to be a summative
 interaction of effects on various pathways.
Overall this unlikely therapeutic tool is implicating novel
pathways as viable therapeutic targets. This opens the way
for the development of other rational, hypothesis-based ther-
apies. That NAC appears safe, tolerable and affordable and is
readily available adds to its interest.
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